Silico Biosciences

Silico Biosciences is an AI-driven drug discovery company focused on leveraging silicon-based machine intelligence to design and generate novel therapeutic molecules. The company's core mission is to harness the power of artificial intelligence to produce antibody sequences and protein structures that replicate the outcomes of billions of years of biological evolution — accelerating the path from computational design to life-saving drugs.

Rather than relying on conventional protein language models that generate amino acid sequences folding into essentially random protein structures, Silico Biosciences aims to go further by producing targeted, purposeful designs guided by AI. The company is actively developing tools and models for in silico antibody discovery, with a focus on scalable and reliable drug development pipelines.

Core Technology: peleke-1

• peleke-1 is Silico Biosciences' flagship suite of protein language models designed specifically for targeted antibody sequence generation.
• The suite is built to move beyond random protein structure generation, producing antibody sequences with intentional, guided design outcomes.
• peleke-1 represents the company's latest and primary research and development project in AI-guided antibody design.

Therapeutic Target Areas

• Oncology targets: Silico Biosciences is actively working on antibody design against key cancer-related targets, including PD-1 and EGFR, both of which are well-established and clinically validated oncology targets.
• Viral targets: The company is also pursuing antibody design against viral pathogens, with Nipah virus identified as a current focus area.

Company Stage and Outlook

• Silico Biosciences is in an early, active development phase and is preparing to onboard beta testers for its platform and models in the near future.
• The company is seeking collaborators and early adopters interested in exploring AI-powered antibody discovery capabilities.

Silico Biosciences sits at the intersection of computational biology and therapeutic development, working to translate AI-generated molecular insights into practical drug discovery outcomes across oncology and infectious disease.